|
1
|
Tian W, Wang G, Liu Y, Huang Z, Zhang C,
Ning K, Yu C, Shen Y, Wang M, Li Y, et al: The miR-599 promotes
non-small cell lung cancer cell invasion via SATB2. Biochem Biophys
Res Commun. 485:35–40. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang D, Ma J, Ji X, Xu F and Wei Y:
miR-141 regulation of EIF4E expression affects docetaxel
chemoresistance of non-small cell lung cancer. Oncol Rep.
37:608–616. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang H, Shen Q, Zhang X, Yang C, Cui S,
Sun Y, Wang L, Fan X and Xu S: The long non-coding RNA XIST
controls non-small cell lung cancer proliferation and invasion by
modulating miR-186-5p. Cell Physiol Biochem. 41:2221–2229. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang J, Wang Y, Sun D, Bu J, Ren F, Liu B,
Zhang S, Xu Z, Pang S and Xu S: miR-455-5p promotes cell growth and
invasion by targeting SOCO3 in non-small cell lung cancer.
Oncotarget. 8:114956–114965. 2017.PubMed/NCBI
|
|
5
|
Wang K, Dong L, Fang Q, Xia H and Hou X:
Low serum miR-98 as an unfavorable prognostic biomarker in patients
with non-small cell lung cancer. Cancer Biomark. 20:283–288. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang L, Liu W, Zhang YP and Huang XR: The
miR-224 promotes non-small cell lung cancer cell proliferation by
directly targeting RASSF8. Eur Rev Med Pharmacol Sci. 21:3223–3231.
2017.PubMed/NCBI
|
|
7
|
Wang M, Meng B and Liu Y, Yu J, Chen Q and
Liu Y: MiR-124 inhibits growth and enhances radiation-induced
apoptosis in non-small cell lung cancer by inhibiting STAT3. Cell
Physiol Biochem. 44:2017–2028. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang P, Chen D, Ma H and Li Y: LncRNA
SNHG12 contributes to multidrug resistance through activating the
MAPK/Slug pathway by sponging miR-181a in non-small cell lung
cancer. Oncotarget. 8:84086–84101. 2017.PubMed/NCBI
|
|
9
|
Wang P, Deng Y and Fu X: MiR-509-5p
suppresses the proliferation, migration, and invasion of non-small
cell lung cancer by targeting YWHAG. Biochem Biophys Res Commun.
482:935–941. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang SY, Li Y, Jiang YS and Li RZ:
Investigation of serum miR-411 as a diagnosis and prognosis
biomarker for non-small cell lung cancer. Eur Rev Med Pharmacol
Sci. 21:4092–4097. 2017.PubMed/NCBI
|
|
11
|
Li J, Tan Q, Yan M, Liu L, Lin H, Zhao F,
Bao G, Kong H, Ge C, Zhang F, et al: miRNA-200c inhibits invasion
and metastasis of human non-small cell lung cancer by directly
targeting ubiquitin specific peptidase 25. Mol Cancer. 13:1662014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Meng F, Zhang L, Shao Y, Ma Q and Lv H:
MicroRNA-377 inhibits non-small-cell lung cancer through targeting
AEG-1. Int J Clin Exp Pathol. 8:13853–13863. 2015.PubMed/NCBI
|
|
13
|
Weber DG, Brik A, Casjens S, Burek K,
Lehnert M, Pesch B, Taeger D, Brüning T and Johnen G; MoMar study
Group, : Are circulating microRNAs suitable for the early detection
of malignant mesothelioma? Results from a nested case-control
study. BMC Res Notes. 12:772019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
do Amaral AE, Cisilotto J, Creczynski-Pasa
TB and de Lucca Schiavon L: Circulating miRNAs in nontumoral liver
diseases. Pharmacol Res. 128:274–287. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wei J, Gao W, Zhu CJ, Liu YQ, Mei Z, Cheng
T and Shu YQ: Identification of plasma microRNA-21 as a biomarker
for early detection and chemosensitivity of non-small cell lung
cancer. Chin J Cancer. 30:407–414. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dinh TK, Fendler W, Chalubinska-Fendler J,
Acharya SS, O'Leary C, Deraska PV, D'Andrea AD, Chowdhury D and
Kozono D: Circulating miR-29a and miR-150 correlate with delivered
dose during thoracic radiation therapy for non-small cell lung
cancer. Radiat Oncol. 11:612016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ye FG, Song CG, Cao ZG, Xia C, Chen DN,
Chen L, Li S, Qiao F, Ling H, Yao L, et al: Cytidine deaminase axis
modulated by miR-484 differentially regulates cell proliferation
and chemoresistance in breast cancer. Cancer Res. 75:1504–1515.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu Y, Xie H, Liu Y, Liu W, Liu M and Tang
H: miR-484 suppresses proliferation and epithelial-mesenchymal
transition by targeting ZEB1 and SMAD2 in cervical cancer cells.
Cancer Cell Int. 17:362017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li T, Ding ZL, Zheng YL and Wang W:
MiR-484 promotes non-small-cell lung cancer (NSCLC) progression
through inhibiting Apaf-1 associated with the suppression of
apoptosis. Biomed Pharmacother. 96:153–164. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Osmani L, Askin F, Gabrielson E and Li QK:
Current WHO guidelines and the critical role of immunohistochemical
markers in the subclassification of non-small cell lung carcinoma
(NSCLC): Moving from targeted therapy to immunotherapy. Semin
Cancer Biol. 52:103–109. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ofori JK, Salunkhe VA, Bagge A, Vishnu N,
Nagao M, Mulder H, Wollheim CB, Eliasson L and Esguerra JL:
Elevated miR-130a/miR130b/miR-152 expression reduces intracellular
ATP levels in the pancreatic beta cell. Sci Rep. 7:449862017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang T, Liu X, Tian Q, Liang T and Chang
P: Increasing expression of miR-5100 in non-small-cell lung cancer
and correlation with prognosis. Eur Rev Med Pharmacol Sci.
21:3592–3597. 2017.PubMed/NCBI
|
|
24
|
Wang Y, Cong W, Wu G, Ju X, Li Z, Duan X,
Wang X and Gao H: MiR-376a suppresses the proliferation and
invasion of non-small-cell lung cancer by targeting c-Myc. Cell
Biol Int. 42:25–33. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang Z, Liu Z, Fang X and Yang H:
MiR-142-5p suppresses tumorigenesis by targeting PIK3CA in
non-small cell lung cancer. Cell Physiol Biochem. 43:2505–2515.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wei K, Pan C, Yao G, Liu B, Ma T, Xia Y,
Jiang W, Chen L and Chen Y: MiR-106b-5p promotes proliferation and
inhibits apoptosis by regulating BTG3 in non-small cell lung
cancer. Cell Physiol Biochem. 44:1545–1558. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yi R, Feng J, Yang S, Huang X, Liao Y, Hu
Z and Luo M: miR-484/MAP2/c-Myc-positive regulatory loop in glioma
promotes tumor-initiating properties through ERK1/2 signaling. J
Mol Histol. 49:209–218. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Merhautova J, Hezova R, Poprach A,
Kovarikova A, Radova L, Svoboda M, Vyzula R, Demlova R and Slaby O:
miR-155 and miR-484 Are associated with time to progression in
metastatic renal cell carcinoma treated with sunitinib. Biomed Res
Int. 2015:9419802015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Halvorsen AR, Sandhu V, Sprauten M, Flote
VG, Kure EH, Brustugun OT and Helland Å: Circulating microRNAs
associated with prolonged overall survival in lung cancer patients
treated with nivolumab. Acta Oncol. 57:1225–1231. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen X, Hu Z, Wang W, Ba Y, Ma L, Zhang C,
Wang C, Ren Z, Zhao Y, Wu S, et al: Identification of ten serum
microRNAs from a genome-wide serum microRNA expression profile as
novel noninvasive biomarkers for nonsmall cell lung cancer
diagnosis. Int J Cancer. 130:1620–1628. 2012. View Article : Google Scholar : PubMed/NCBI
|
